Cargando…
Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study
BACKGROUND: Apatinib showed promising efficacy in the treatment of advanced or metastatic gastric cancer (mGC) in previous clinical studies. However, the real-world data are limited, and this study aimed to assess the effectiveness and safety of apatinib for the treatment of advanced or mGC in this...
Autores principales: | Shen, Bo, Jiang, Hua, Wang, Lin, Qian, Jun, Shu, Yongqian, Chen, Ping, Mao, Guoxin, Liu, Baorui, Zhang, Xizhi, Liu, Chaoying, Wu, Jun, Li, Xiaoqin, Cai, Wei, Shen, Wenxiang, Wang, Qiong, He, Jingdong, Hua, Dong, Zhang, Ziwen, Zhang, Youcheng, Feng, Jifeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246318/ https://www.ncbi.nlm.nih.gov/pubmed/32547076 http://dx.doi.org/10.2147/OTT.S232287 |
Ejemplares similares
-
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019) -
Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
por: Tang, Zhaoqing, et al.
Publicado: (2022) -
Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020
por: Hsu, Andrew, et al.
Publicado: (2020) -
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020) -
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
por: Jing, Chao, et al.
Publicado: (2022)